CLOV earnings call summary

Prepared Highlights

• Membership: Q2 2025 MA membership grew 32% YoY to 106,000+ members; full-year 2025 average membership guidance raised to 104,000–108,000 (CFO).
• Insurance revenue: Q2 2025 insurance revenue $470M (+34% YoY); year-to-date $927M (+34% YoY); full-year 2025 guidance reconfirmed at $1.800B–$1.875B (37% YoY growth at midpoint) (CFO).
• Insurance BER: Q2 2025 BER 88.4% vs 76.1% in Q2 2024; year-to-date 87.3%; full-year 2025 BER guidance raised to 88.5%–89.5% (CFO).
• Adjusted EBITDA: Q2 2025 adjusted EBITDA $70M; year-to-date $43M (flat YoY despite 32% membership growth); full-year 2025 guidance maintained at $50M–$70M (CFO).
• Adjusted net income: Q2 2025 adjusted net income $70M; year-to-date $42M; full-year 2025 guidance maintained at $50M–$70M (CFO).
• Adjusted SG&A: Q2 2025 adjusted SG&A as % of total revenue improved to 17% (280 bps YoY improvement); full-year 2025 adjusted SG&A guidance improved to $335M–$345M (18%–19% of total revenue) (CFO).
• GAAP net loss: Q2 2025 GAAP net loss $11M; year-to-date GAAP net loss $12M, improved by $4M YoY (CFO).
• Cash & investments: $389M consolidated at Q2 2025 end; $146M at unregulated subsidiary level (CFO).
• Days in claims payable: 32 days as of June 30, 2025, down 5 days sequentially (CFO).
• Plan type: 97% of members enrolled in wide-network PPO plan (CEO, CFO).
• Stars rating: Moving from 3.5-star (2025) to 4-star (2026) for PPO plans, providing financial tailwind (CEO, CFO).
• RPO/backlog: Not stated.

Official Guidance (Full-Year 2025)

• MA membership (average): 104,000–108,000 (CFO).
• Insurance revenue: $1.800B–$1.875B (CFO).
• Insurance BER: 88.5%–89.5% (CFO).
• Adjusted SG&A: $335M–$345M (CFO).
• Adjusted EBITDA: $50M–$70M (CFO).
• Adjusted net income: $50M–$70M (CFO).

Mgmt Quotes

• (CEO): "We have always aimed to position Clover to win over the long term within Medicare Advantage and our arc has been simple: first, achieve profitability; then return to growth while sustaining profitability; and then leverage our differentiated model to accelerate growth and profitability together."
• (CEO): "While not all market plan data is available yet, we have reason to believe this will be another strong membership growth season for us. Potentially even stronger than this year."
• (CEO): "Our trajectory is clear. We are confident in the path ahead."
• (CFO): "We are demonstrating great Medicare panic execution, leading with a wide network PPO plan that currently serves 97% of our members. We have achieved over 30% membership growth, which is well above the industry, all while maintaining profitability on a 3.5 star payment year."
• (CFO): "We expect that our cash balances will remain strong for the remainder of 2025, which will allow us to continue to operate from a position of strength, as we invest in our growth model in 2026 and beyond."

Prepared Metrics

Q&A Batch (1-1 of 1)

Q1 — Unidentified Analyst

• Topic: MCR/BER 指引上修原因及下半年趋势可见性
• Key points:
  • MCR/BER 上修主要由 Part D 和补充福利（尤其是牙科）驱动。
  • IRA 实施第一年，行业对 Part D 模型仍在调整中；管理层认为 2026 年 Part D 压力有望因 IRA 缓解。
  • 管理层已将 Part D 成本压力纳入 2026 年定价标的，行业普遍在投标中考虑更高 Part D 成本。
• Mgmt stance: 谨慎偏中性。承认 Part D 成本超预期，但强调已启动监控措施，并预期 2026 年定价可吸收影响。

Q2 — Matthew Gregory Hewitt (Craig-Hallum)

• Topic: 调整后 SG&A 改善的驱动因素及 COPD 白皮书后续计划
• Key points:
  • SG&A 改善来自全公司成本效率举措，包括重新谈判合作协议中的价格和条款——得益于公司增长领先行业且未来数年增长可期，成为更具吸引力的合作伙伴。
  • COPD 白皮书已发布；此前还有 CHF（约 2 个月前）及 CKD（去年或前年）白皮书，均显示 Clover Assistant 与护理管理和总护理成本改善相关。
  • HEDIS 评分仍为全国顶尖，这些数据被用于向其他计划推广技术。
• Mgmt stance: 乐观。强调成本优化能力增强，并展示技术成果可复制推广。

Q3 — John Granville Pinney (Canaccord Genuity)

• Topic: 成本趋势分布、竞争格局及 2026 AEP 展望
• Key points:
  • 成本压力（Part D 和补充福利）非集中在新老成员特定组别，而是广泛分布；老成员 MCR/BER 持续改善。
  • 2026 年直接补贴将增加，管理层认为行业将合理定价当前 Part D 压力。
  • 竞争对手普遍削减 Medicare Advantage 产品，Clover 认为自身技术驱动模式可更好地管理成本。
• Mgmt stance: 乐观。强调新老成员表现符合预期，且行业调整对自身模式有利。